Across the two pivotal trials, Rinvoq delivered rapid and meaningful disease control with nearly half of ankylosing spondylitis (AS) patients achieving ASAS40 (51% and 44.5% with Rinvoq versus 26% and 18.2% with placebo) at week 14 compared…Original Article
Rinvoq (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis
